DLBCL - diffuse large B cell lymphoma
Clinical trials for DLBCL - diffuse large B cell lymphoma explained in plain language.
Never miss a new study
Get alerted when new DLBCL - diffuse large B cell lymphoma trials appear
Sign up with your email to follow new studies for DLBCL - diffuse large B cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Double punch: CAR-T cells followed by antibodies may boost lymphoma remission
Disease control OngoingThis study tests whether giving additional antibody drugs (mosunetuzumab or glofitamab plus obinutuzumab) after CAR-T cell therapy can improve outcomes for people with relapsed or refractory large B-cell lymphoma. About 23 participants will receive the combination to see if it le…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase 2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New CAR-T therapy targets Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses specially engineered immune cells from a healthy donor to attack cancer cells. T…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase 1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can a quick radiation boost make CAR T-Cell therapy work better for lymphoma?
Disease control OngoingThis early-phase trial is testing whether giving low-dose radiation before CAR T-cell therapy is feasible and safe for people with B-cell lymphoma that has come back or not responded to treatment. About 33 participants will receive two small doses of radiation, then standard CAR …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase 1 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
15-Year watch begins for new cancer cell therapy
Knowledge-focused By invitation onlyThis study follows 18 people who previously received GF-CART01, a CAR T-cell therapy for certain blood cancers like lymphoma. Researchers will track side effects and how long the modified cells last in the body for up to 15 years. The goal is to ensure the treatment remains safe …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC